Investigational Products
AT177 and Azora Therapeutics’ other product candidates are investigational and have not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not been established, and no conclusion regarding safety or efficacy can or should be drawn from the information presented on this website. Clinical and preclinical findings described here, including findings relating to indigo naturalis, are drawn from published third-party research and from company data on file; results observed with any other agent are not predictive of results that may be observed with AT177. Nothing on this site is medical advice, an offer to sell or a solicitation to buy any security, or a promotion of any unapproved product or unapproved use of a product.
Trademarks
Azora™, Azora Therapeutics and the Azora logo are trademarks of Azora Therapeutics, Inc. All other product names, logos, brands and trademarks appearing on this site are the property of their respective owners. Their use does not imply any affiliation with, endorsement or sponsorship by, or partnership with those owners, and Azora Therapeutics asserts no ownership of or right in those marks. Where third-party products are referenced, they are referenced solely to describe the prior professional experience of members of Azora’s team and advisors.
Forward-Looking Statements
This website contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the development of AT177, planned IND filing and clinical trials, anticipated timing of data, market opportunity, and intellectual property. These statements are based on current expectations and assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially. Product candidates are investigational, have not been approved by the FDA or any regulatory authority, and their safety and efficacy have not been established. Market, competitive, and clinical figures presented are drawn from company materials and third-party sources and are subject to review. Azora undertakes no obligation to update any forward-looking statement except as required by law. Please refer to the company's filings with the U.S. Securities and Exchange Commission for additional information.
NASDAQ: AZR · © 2026 Azora Therapeutics, Inc. All rights reserved. · Privacy Policy · Terms of Use · Accessibility Statement
